The extent of extranodal extension as a prognostic indicator in papillary thyroid cancerAbstract
Objective: Extranodal extension (ENE) is acknowledged as a significant prognostic factor associated with recurrence, distant metastasis, and reduced disease-specific survival in patients with papillary thyroid carcinoma. However, the impact of the extent of extranodal extension on the clinical outcomes of these patients remains insufficiently understood. This study aimed to estimate the risk of detecting distant metastasis in patients with varying degrees of ENE according to a novel stratification method.
Materials and methods: This retrospective study utilizes medical records and slide reviews of papillary thyroid cancer patients who underwent therapeutic neck dissection. A new stratification system was developed, based on the circumferential rupture of the lymph node capsule. It is defined as Focal ENE when less than one-third of the lymph node capsule is ruptured and as Diffuse ENE when one-third or more of the capsule is involved.
Results: Eighty-nine patients participated in the study, with 19% diagnosed with distant metastasis within a 96-month follow-up period. The presence of diffuse extranodal extension was associated with a risk approximately six times higher than in patients without ENE for the detection of distant metastasis at 96 months, after adjustment for age group (HR = 6.41; 95% CI: 1.7-23.8; p = 0.006).
Conclusion: A greater extent of extranodal extension is linked to a heightened risk of detecting distant metastasis and should thus be considered in the therapeutic decision-making process.
Keywords:
Papillary thyroid cancer; extranodal extension; prognosis; metastasis
INTRODUCTION
The incidence of thyroid cancer has been increasing in recent decades, primarily due to a rise in well-differentiated thyroid carcinoma cases (1). These carcinomas constitute approximately 90% of new thyroid cancer cases in both men and women, with most being of the papillary subtype (2). Papillary thyroid carcinomas are generally slow-growing tumors and have the best survival rates among all types of thyroid cancer (3). However, some patients experience challenging clinical outcomes, making the identification of prognostic factors for these patients a subject of study in recent decades (4-9).
While certain prognostic factors, such as being aged ≥ 54 years, larger tumor size, extrathyroidal extension, angiolymphatic invasion, and aggressive histological variants, are well-known, controversies persist regarding the significance of some features of regional metastases, such as the number of positive lymph nodes, size of affected lymph nodes, and the presence of extranodal extension (5).
Extranodal extension refers to the invasion of tumor cells beyond the capsule of a lymph node into the surrounding soft tissue (10). The current classification of extranodal extension for head and neck tumors, as well as other cancers, is divided into microscopic ENE, where the tumor extends beyond the lymph node capsule by up to 2 mm, and macroscopic ENE, where the invasion exceeds 2 mm, as adopted by several authors (11). Recently, new histopathological classifications of the degree of extranodal extension have been proposed, based on the specific characteristics of the tumor understudy (12,13).
The risk stratification system validated by the American Thyroid Association recognizes three lymph node criteria as predictors of recurrence risk: the number of positive lymph nodes, the size of the largest affected lymph node, and the number of lymph nodes with extranodal extension (14). However, the American Thyroid Association classification system does not subdivide extranodal extension into microscopic and macroscopic categories, as adopted by some authors (15,16).
Conversely, the American Joint Committee on Cancer (AJCC) staging system considers only the presence of metastasis in the central (N1a) or lateral compartments (N1b) for the prognosis of patients with papillary thyroid carcinoma. This contrasts with the staging system for head and neck squamous cell carcinoma, where lymph node size, site of nodal disease, and extranodal extension are considered, with the latter being incorporated in its latest edition (17).
In papillary thyroid carcinoma, the presence of extranodal extension is known to be associated with an increased risk of metastasis, recurrence, and disease-specific survival (18,19). The presence of more than three lymph nodes with extranodal extension is associated with recurrence in this type of cancer (4).
Extranodal extension visible to the naked eye has been shown to decrease survival in patients with papillary thyroid carcinoma (16). However, the relationship between the extent of microscopic extranodal extension and its impact on the prognosis of patients with papillary thyroid carcinoma remains uncertain.
This study evaluated whether a greater extent of microscopic extranodal extension in papillary thyroid carcinoma is associated with a higher risk of detecting distant metastasis. Additionally, a classification of extranodal extension focused on the specific characteristics of papillary thyroid carcinoma is proposed, aiming to improve prognostic stratification.
MATERIALS AND METHODS
This observational cohort study, which involves retrospective data collection and the review of histopathological slides, included patients aged 18 years or older with papillary thyroid carcinoma. These patients underwent therapeutic cervical lymph node dissection at the National Cancer Institute (INCA) in Rio de Janeiro between 2009 and 2014 (Figure 1). The profile of patients at our institution comprises both treatment-naïve individuals and those who underwent previous surgeries elsewhere. Candidates for neck dissection at our institution are patients with suspicious cervical lymph nodes identified clinically or through imaging examinations, confirmed by FNAB or intraoperative frozen section analysis. Patients with distant metastases prior to lymph node dissection or slides unsuitable for review were excluded from the study.
Flowchart of the sample. Out of the 102 patients who underwent surgical interventions during the specified period, 13 were excludedª.
Prognostic data were collected independently of the slide review, and the pathologist was blinded to the outcomes of the patients whose slides were reviewed. Patients were followed for eight years from the date of the first cervical lymph node dissection. Distant metastases detected within the eight-year follow-up were considered, while those occurring beyond this period were censored. The presence of distant metastasis was evaluated using positron emission tomography with 18F-fluorodeoxyglucose, computed tomography, magnetic resonance imaging, or whole-body scans. Imaging tests were requested only when lung metastases were suspected during follow-up.
The tissue blocks and slides were stained previously with Hematoxylin-Eosin. The criteria from the latest edition of the AJCC were used to define extranodal extension, referring to the penetration of tumor cells beyond the lymph node capsule into the perinodal soft tissue. Extranodal extension was classified by the following system proposed by the authors: Focal ENE - less than one-third of the lymph node capsule was ruptured; Diffuse ENE - one-third or more of the lymph node capsule was ruptured. Patients with two or more lymph nodes showing extranodal extension were classified according to the lymph node with the greatest extent of extranodal extension.
Clinical, therapeutic, and pathological characteristics of the study population were described using tables with absolute and relative frequencies. Differences in categorical variables were assessed with Fisher’s exact test.
To estimate the cumulative incidence of distant metastasis diagnosis at eight years, the non-parametric Kaplan-Meier product estimator was used. The initial event was the first therapeutic neck dissection performed at INCA for papillary thyroid carcinoma treatment, while the final event was the diagnosis of distant metastasis or the end of follow-up for those who did not experience this outcome during the eight-year follow-up.
Variables with a p < 0.05 in the log-rank test were initially considered for inclusion in the Cox models with a single covariate. In creating the multivariate Cox model, the authors assessed collinearity among candidate variables, retaining only those deemed clinically relevant and not highly correlated. Specifically, ENE degree, the number of lymph nodes with ENE, and the presence/absence of ENE were highly correlated variables; therefore, only the degree of ENE was included in the final model. Likewise, the variable “angiolymphatic invasion” showed a significant association in the single covariate analysis, but with a paradoxical direction of effect (patients without invasion having a higher risk of distant metastasis). Given the limited number of events and the lack of biological plausibility, this result was interpreted as potentially due to chance (type I error), and angiolymphatic invasion was not included in the multivariate Cox model. Thus, the final model was adjusted for age and the degree of ENE, the variables with the strongest clinical plausibility and statistical stability. Data consistency and statistical analysis were performed using Stata 15 software.
This study adhered to the guidelines of Resolution nº 466/2012 of the Brazilian National Health Council and was approved the Research Ethics Committee of INCA. Study number 517.819 was approved on January 29, 2014. The research was conducted according to ethical principles, ensuring patient confidentiality and privacy throughout the study.
New proposed classification system for extranodal extension
Considering the biological characteristics of cervical metastases in papillary thyroid carcinoma, where even small metastases in the central compartment can exhibit ENE, we propose a new classification system. This system is based on the circumferential rupture of the lymph node capsule and its proportionality relative to the lymph node, rather than solely measuring tumor extension into the perinodal fat.
ENE was classified as focal when the tumor ruptured the lymph node capsule by less than one-third of its circumference (Figure 2A), and as diffuse when the rupture extended to more than one-third of its circumference (Figure 2B).
Lymph node metastasis in papillary thyroid carcinoma (H&E, x40). A metastatic tumor rupturing the lymph node capsule and extending into the perinodal fat is shown focally (less than one-third in and diffusely (more than one-third) in B.
This assessment better reflects the unique biological behavior of papillary thyroid carcinoma when compared to the current classification proposed by the AJCC. The AJCC definition considers macroscopic extranodal extension when the lymph node capsule is ruptured and there is tumor invasion into the perinodal fat of more than 2 mm, regardless of the extent of the lymph node capsule rupture.
RESULTS
Clinical, therapeutic, and histopathological characteristics of patients with papillary thyroid carcinoma
Of the 89 patients included in the study, 17 developed distant metastasis within 96 months of follow-up. Among these 17 patients, all had pulmonary metastasis, and one-fourth exhibited metastasis to more than one site. The average time to metastasis occurrence was approximately 33 months. About 75% of the patients were female and under the age of 54. Most patients (71%) who were diagnosed with metastases had tumors larger than 4 cm, and more than half were classified as T3 and T4 according to the AJCC 8th edition staging. However, it should be noted that data was missing for more than 25% of the patients since many underwent their initial surgery at an institution other than the one where this study was conducted (Table 1).
Distribution of patients with papillary thyroid carcinoma undergoing therapeutic cervical lymph node dissection, by development of distant metastasis within eight years, and according to clinical, therapeutic, and histopathological characteristics
Regarding lymph node sites, all patients who developed distant metastasis had disease in the lateral compartment. Extranodal extension was present in a little over half of the patients (45/89), and among these, most exhibited diffuse extranodal extension (25/45). Among those who developed metastasis, more than 80% had extranodal extension, with a majority presenting diffuse extranodal extension. Approximately 40% of patients had between one and three lymph nodes with extranodal extension, while only 10% had four or more lymph nodes exhibiting the same characteristic. Notably, for patients diagnosed with metastasis, 60% had between one and three lymph nodes affected (Table 1).
Concerning therapeutic response, among the patients who detected distant metastasis, more than 80% had structural disease after neck dissection. In contrast, among those without distant metastasis, 47% exhibited an excellent response following neck dissection. In both the M0 and M1 groups, less than half of the patients underwent additional surgical intervention in the neck (Table 1).
The probability of detecting distant metastasis is greater among patients with a higher extent of extranodal extension.
The overall probability of detecting metastasis within 96 months was 20.4%. While patients without extranodal extension had a 7.1% probability (95% CI, 2.3-20.4) of detecting distant metastasis within eight years, those with focal extranodal extension had a 28.2% probability (95% CI, 12.7-55.5). For patients with diffuse extranodal extension, the probability was 37.7% (95% CI, 21.6-60.2) (p = 0.006) (Supplementary Table 1). In summary, a greater extent of extranodal extension is associated with an increased probability of detecting distant metastasis within eight years (Figure 3).
Estimated probabilities of detecting distant metastasis related to the extent of extranodal extension in patients with papillary thyroid carcinoma undergoing therapeutic cervical lymph node dissection.
The presence of a higher degree of ENE represents a sixfold greater risk of diagnosing distant metastasis compared to patients without ENE. In the analysis of single covariate Cox models, it was observed that in patients aged 55 years and above, the presence of extranodal extension, more than three lymph nodes with extranodal extension, and a higher extent of extranodal extension conferred a greater risk of diagnosing distant metastasis (Table 2).
Factors influencing the likelihood of detecting distant metastasis within 96 months in patients with papillary thyroid carcinoma undergoing therapeutic neck dissection
After evaluating collinearity and robustness of associations, the final multivariate model was adjusted for age and the degree of extranodal extension (Supplementary Table 2). Patients with diffuse extranodal extension have a sixfold greater risk of developing distant metastasis within 96 months (95% CI: 1.7-23.8), compared to those without this characteristic. This condition remains significant even after adjustment for age (Table 2).
DISCUSSION
Our findings indicated that patients with a higher degree of extranodal extension have an increased likelihood of detecting distant metastases among those with papillary thyroid carcinoma. A new classification for the extent of extranodal extension, which considers the characteristics of metastases in papillary thyroid carcinoma, has been proposed. Even with small lymph nodes in the central compartment, extranodal extension can still occur. Extranodal extension is termed focal when the tumor breaches the lymph node capsule by less than one-third of its circumference (Figure 1A), and “diffuse” when the rupture extends to more than one-third of its circumference (Figure 1B). The presence of diffuse extranodal extension indicates a worse prognosis in patients with papillary thyroid carcinoma.
Approximately 19% of the patients in this study presented with distant metastasis. Previous studies have shown that this percentage varies between 2%-10% (20-22). However, this discrepancy between our findings and those of other studies may be attributed to our study population, which consisted of intermediateand high-risk patients, unlike other studies that included patients with a lower likelihood of detecting distant metastasis.
The patients who presented with extranodal extension represented just over half of the study population. These results are analogous to those presented by Kim and cols. (23) in a retrospective study conducted at Samsung Medical Center in Korea, which found extranodal extension in 193 out of 369 patients (52%) with papillary thyroid carcinoma and cervical nodal disease (23).
This proportion is higher than that found by other authors (19). This difference may be attributed to the evolving definition of extranodal extension, which has undergone numerous changes over the years and has been standardized more recently (10,24,25). This new definition was used in our study, as well as in the study by Kim and cols. (23), with similar results.
All patients who presented distant metastasis had positive lymph nodes in the lateral compartment, and none of those with lymph nodes exclusively in the central compartment developed distant metastasis. In a meta-analysis by Vuong and cols. (22), three studies comprising 1,072 patients with papillary thyroid carcinoma investigated the relationship between the presence of positive lymph nodes in the central compartment and distant metastasis. The results showed that patients with central compartment lymph nodes did not present a significant risk for distant metastasis (OR = 0.82; 95% CI 0.25-2.72). Conversely, patients with lateral lymph nodes had a significantly higher risk of distant metastasis (OR = 5.75, 95% CI 2.91-11.36), thus corroborating the findings that nodal disease in the central compartment does not significantly impact the prognosis of patients with papillary thyroid carcinoma as it does in the lateral cervical compartment.
The presence of extranodal extension represented a higher risk of detecting distant metastasis among the patients in the study, as evidenced by the difference between the curves of patients with and without extranodal extension (Figure 2). Sugitani and cols. (26) were the first authors to describe the close relationship between distant metastasis in papillary thyroid carcinoma and extranodal extension, observing its presence as a common feature in many patients who developed distant metastasis. Jeon and cols. (27) reviewed a series of 8,808 patients and found an association between the presence of extranodal extension and distant metastasis even in papillary thyroid microcarcinomas (OR = 5.50; 95% CI 1.08-33.64; p = 0.045). In addition to its influence on the detection of distant metastasis, extranodal extension also impacts disease-specific survival and recurrence in patients with this characteristic (19). Therefore, it is recommended to consider extranodal extension in the histopathological examination of patients with thyroid cancer, and this factor should be included in future staging systems.
The present study identified a higher likelihood of patients detecting distant metastasis in relation to the extent of extranodal extension, presenting a sixfold increased risk of distant metastasis for patients with a greater extent of extranodal extension, regardless of age.
In the series by Ito and cols. (15), patients with extranodal extension were categorized into those with the extension reaching adjacent organs and those with metastatic nodules completely invading adjacent organs. The authors did not find statistically significant differences in the prognosis of these two groups. However, it is likely that the absence of differences in patient outcomes based on Ito and cols.’ criteria is due to the use of only macroscopic criteria to define extranodal extension, excluding patients who exhibited this characteristic solely on a microscopic level, as was performed in our cohort.
Among the limitations of this study are the limited number of patients facing a rare outcome and the lack of comparability with existing classifications. Given the relatively small sample size of 89 patients, the statistical power of the study may be limited, necessitating cautious interpretation of the results. An important aspect concerns the selection of variables for the multivariate model. Although angiolymphatic invasion showed a statistically significant association in the univariate analysis, the effect was paradoxical, with patients without angiolymphatic invasion exhibiting a higher risk of distant metastasis. We interpreted this as a spurious finding, likely related to the limited number of events and a type I error; hence, angiolymphatic invasion was not retained in the final model. Additionally, the degree of ENE and the number of lymph nodes with ENE are strongly correlated variables. To avoid multicollinearity and unstable estimates, we opted to include only the degree of ENE in the final analysis. This strategy aimed to enhance the reliability and interpretability of the results. Furthermore, the slides were analyzed by only one pathologist, although this pathologist has decades of experience with this type of cancer.
Due to the retrospective nature of our study, patients did not undergo standardized imaging workups to screen for distant metastases prior to surgery. Consequently, the documented date of diagnosis corresponds to the time of detection and does not exclude the possibility that metastases were present at the time of surgery but remained undiagnosed. Although the indolent behavior of the CPT corroborates the hypothesis that distant metastasis occurs after spreading to the neck, this analysis should be approached with caution.
To our knowledge, this study is the first to propose a classification of microscopic extranodal extension that considers the specific characteristics of papillary thyroid carcinoma metastases for patients’ prognosis.
Future studies with larger patient populations that compare our newly proposed classification with existing ones are essential for a better understanding of the impact of the degree of extranodal extension and its applicability. Understanding this tumor feature may also be important to define the appropriate follow-up time for patients. It may also assist in better determining the indication and dose of radioiodine therapy for intermediate-risk patients. Clinical studies are needed to assess whether therapeutic changes could influence the development of distant metastasis.
SUPPLEMENTARY MATERIAL
Probability of developing distant metastasis within 96 months in patients with papillary thyroid carcinoma undergoing therapeutic cervical lymph node dissection, according to clinical, therapeutic, and histopathological characteristics
Data availability:
datasets related to this article will be available upon request to the corresponding author.
REFERENCES
-
1 Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. Nat Rev Endocrinol. 2016 Nov;12(11):646-53. doi: 10.1038/nrendo.2016.110.
» https://doi.org/10.1038/nrendo.2016.110. -
2 Noone AM, Cronin KA, Altekruse SF, Howlader N, Lewis DR, Petkov VI, et al. Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992-2013. Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):632-41. doi: 10.1158/1055-9965.EPI-16-0520. E
» https://doi.org/10.1158/1055-9965.EPI-16-0520. -
3 Tam S, Boonsripitayanon M, Amit M, Fellman BM, Li Y, Busaidy NL, et al. Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions. Thyroid. 2018 Oct;28(10):1301-10. doi: 10.1089/thy.2017.0572.
» https://doi.org/10.1089/thy.2017.0572. -
4 Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl DM, Bidart JM, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005 Oct;90(10):5723-9. doi: 10.1210/jc.2005-0285.
» https://doi.org/10.1210/jc.2005-0285. -
5 Nixon IJ, Kuk D, Wreesmann V, Morris L, Palmer FL, Ganly I, et al. Defining a Valid Age Cutoff in Staging of Well-Differentiated Thyroid Cancer. Ann Surg Oncol. 2016 Feb;23(2):410-5. doi: 10.1245/s10434-015-4762-2.
» https://doi.org/10.1245/s10434-015-4762-2. -
6 Shaha AR, Shah JP, Loree TR. Risk group stratification and prognostic factors in papillary carcinoma of thyroid. Ann Surg Oncol. 1996 Nov;3(6):534-8. doi: 10.1007/BF02306085.
» https://doi.org/10.1007/BF02306085. -
7 Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol). 2010 Aug;22(6):395-404. doi: 10.1016/j.clon.2010.05.004.
» https://doi.org/10.1016/j.clon.2010.05.004. -
8 Sugino K, Ito K, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa K, et al. Prognosis and Prognostic Factors for Distant Metastases and Tumor Mortality in Follicular Thyroid Carcinoma. Thyroid. 2011 Jul;21(7):751-7. doi: 10.1089/thy.2010.0353.
» https://doi.org/10.1089/thy.2010.0353. -
9 Wang L, Liu X. Cervical sagittal alignment in adolescent idiopathic scoliosis patients (Lenke type 1-6). J Orthop Sci. 2017 Mar;22(2):254-9. doi: 10.1016/j.jos.2016.12.006.
» https://doi.org/10.1016/j.jos.2016.12.006. -
10 Abdel-Halim CN, Rosenberg T, Larsen SR, Høilund-Carlsen PF, Sørensen JA, Rohde M, et al. Histopathological Definitions of Extranodal Extension: A Systematic Review. Head Neck Pathol. 2021 Jun;15(2):599-607. doi: 10.1007/s12105-020-01221-4.
» https://doi.org/10.1007/s12105-020-01221-4. -
11 Lydiatt WM, Patel SG, O’Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. Head and neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 Mar;67(2):122-37. doi: 10.3322/caac.21389.
» https://doi.org/10.3322/caac.21389. -
12 Lewis Jr JS, Tarabishy Y, Luo J, Mani H, Bishop JA, Leon ME, et al. Interand intra-observer variability in the classification of extracapsular extension in p16 positive oropharyngeal squamous cell carcinoma nodal metastases. Oral Oncol. 2015 Nov;51(11):985-90. doi: 10.1016/j.oraloncology.2015.08.003.
» https://doi.org/10.1016/j.oraloncology.2015.08.003. -
13 Wang JY, Zhu Y, Tang SX, Zhang HL, Qin XJ, Zhang SL, et al. Prognostic significance of the degree of extranodal extension in patients with penile carcinoma. Asian J Androl. 2014 May-Jun;16(3):437-41. doi: 10.4103/1008-682X.122862.
» https://doi.org/10.4103/1008-682X.122862. -
14 Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020.
» https://doi.org/10.1089/thy.2015.0020. -
15 Ito Y, Hirokawa M, Jikuzono T, Higashiyama T, Takamura Y, Miya A, et al. Extranodal Tumor Extension to Adjacent Organs Predicts a Worse Cause-specific Survival in Patients with Papillary Thyroid Carcinoma. World J Surg. 2007 Jun;31(6):1194-201. doi: 10.1007/s00268-007-9042-2.
» https://doi.org/10.1007/s00268-007-9042-2. -
16 Roh J, Park JW, Jeong J, Gong G, Cho K, Choi S, et al. Extranodal extension of lymph node metastasis as a prognostic indicator of recurrence and survival in papillary thyroid carcinoma. J Surg Oncol. 2017 Sep;116(4):450-8. doi: 10.1002/jso.24713.
» https://doi.org/10.1002/jso.24713. -
17 AJCC. American Joint Comission of Cancer. Cancer Staging Manual [Internet]. 8th ed. USA: Springer International Publishing; 2017 [cited 2024 Jul 4]. Available from: https://jamanetwork.com/journals/jama/article-abstract/186724
» https://jamanetwork.com/journals/jama/article-abstract/186724 -
18 Lango M, Flieder D, Arrangoiz R, Veloski C, Yu JQ, Li T, et al. Extranodal Extension of Metastatic Papillary Thyroid Carcinoma: Correlation with Biochemical Endpoints, Nodal Persistence, and Systemic Disease Progression. Thyroid. 2013 Sep;23(9):1099-105. doi: 10.1089/thy.2013.0027.
» https://doi.org/10.1089/thy.2013.0027. -
19 Veronese N, Luchini C, Nottegar A, Kaneko T, Sergi G, Manzato E, et al. Prognostic impact of extra-nodal extension in thyroid cancer: A meta-analysis. J Surg Oncol. 2015 Dec;112(8):828-33. doi: 10.1002/jso.24070.
» https://doi.org/10.1002/jso.24070. -
20 Clark CJ, Whang S, Paige KT. Incidence of precancerous lesions in breast reduction tissue: a pathologic review of 562 consecutive patients. Plast Reconstr Surg. 2009 Oct;124(4):1033-9. doi: 10.1097/PRS.0b013e3181b45801.
» https://doi.org/10.1097/PRS.0b013e3181b45801. -
21 Shaha AR, Ferlito A, Rinaldo A. Distant metastases from thyroid and parathyroid cancer. ORL J Otorhinolaryngol Relat Spec. 2001 Jul-Aug;63(4):243-9. doi: 10.1159/000055749.
» https://doi.org/10.1159/000055749. -
22 Vuong HG, Duong UNP, Pham TQ, Tran HM, Oishi N, Mochizuki K, et al. Clinicopathological Risk Factors for Distant Metastasis in Differentiated Thyroid Carcinoma: A Meta-analysis. World J Surg. 2018 Apr;42(4):1005-17. doi: 10.1007/s00268-017-4206-1.
» https://doi.org/10.1007/s00268-017-4206-1. -
23 Kim HI, Hyeon J, Park SY, Ahn HS, Kim K, Han JM, et al. Impact of Extranodal Extension on Risk Stratification in Papillary Thyroid Carcinoma. Thyroid. 2019 Jul;29(7):963-70. doi: 10.1089/thy.2018.0541.
» https://doi.org/10.1089/thy.2018.0541. -
24 Brannan AG, Johnstone PAS, Cooper J. Extracapsular tumor extension in cervical lymph nodes: Reconciling the literature and seer data. Head Neck. 2011 Apr;33(4):525-8. doi: 10.1002/hed.21487.
» https://doi.org/10.1002/hed.21487. -
25 Van Den Brekel MWM, Lodder WL, Stel HV, Bloemena E, Leemans CR, Van Der Waal I. Observer variation in the histopathologic assessment of extranodal tumor spread in lymph node metastases in the neck. Head Neck. 2012 Jun;34(6):840-5. doi: 10.1002/hed.21823.
» https://doi.org/10.1002/hed.21823. -
26 Sugitani I, Yanagisawa A, Shimizu A, Kato M, Fujimoto Y. Clinicopathologic and Immunohistochemical Studies of Papillary Thyroid Microcarcinoma Presenting with Cervical Lymphadenopathy. World J Surg. 1998 Jul;22(7):731-7. doi: 10.1007/s002689900461.
» https://doi.org/10.1007/s002689900461. -
27 Jeon MJ, Kim WG, Choi YM, Kwon H, Lee YM, Sung TY, et al. Features Predictive of Distant Metastasis in Papillary Thyroid Microcarcinomas. Thyroid. 2016 Jan;26(1):161-8. doi: 10.1089/thy.2015.0375.
» https://doi.org/10.1089/thy.2015.0375.
Note: ªCPT = papillary thyroid carcinoma; DM = distant metastasis.
